Department of Surgery (Urology), University of Utah, Salt Lake City, Utah.
Department of Urology, University of Michigan, Ann Arbor, Michigan.
Neurourol Urodyn. 2019 Jan;38(1):285-294. doi: 10.1002/nau.23849. Epub 2018 Oct 30.
Clean intermittent catheterization (CIC) is recommended after spinal cord injury (SCI) because it has the least complications, however, CIC has a high discontinuation rate. We hypothesized that bladder botulinum toxin injection or augmentation cystoplasty may improve satisfaction with CIC.
The NBRG registry is a multicenter, prospective, observational study asking SCI participants about neurogenic bladder (NGB) related quality of life (QoL). In this study, participants performing CIC as primary bladder management were categorized into 3 groups: (1) CIC alone (CIC); (2) CIC with botulinum toxin (CIC-BTX); and (3) CIC with augmentation cystoplasty (CIC-AUG). Outcomes included primary: Neurogenic Bladder Symptom Score (NBSS) and SCI-QoL Bladder Management Difficulties, and secondary: NBSS subdomains (Incontinence, Storage & Voiding, Consequences) and the NBSS final question (satisfaction with urinary function). Multivariable regression, controlling for multiple factors was used to establish differences between the three groups.
Eight hundred seventy-nine participants performed CIC as primary bladder management and had the following characteristics: mean age 43.4 (±12.9) and years from injury 13.7 (±10.7), tetraplegia in 284 (32%), and 543 (62%) were men. Bladder management was CIC in 593 (67%), CIC-BTX in 161 (19%), and CIC-AUG in 125(15%). Primary outcomes: CIC-AUG had associated improved total NBSS versus CIC(-3.2(-5.2 to -1.2), P = 0.001 and CIC-BTX(-3.9(-6.3 to -1.6), P = 0.001), CIC-AUG also had better SCI-QoL Difficulties scores versus CIC(-4(-5.48 to -2.53, P < 0.001) and CIC-BTX(-4.4(-6.15 to -2.65, P < 0.001).
CIC-AUG had associated improved Incontinence and Satisfaction scores versus CIC and CIC-BTX.
Compared to patients performing CIC with or without botulinum toxin treatment, those with augmentation cystoplasty had associated better urinary function and satisfaction with their urinary symptoms.
脊髓损伤(SCI)后推荐间歇性导尿(CIC),因为它并发症最少,但 CIC 的中断率很高。我们假设膀胱肉毒毒素注射或膀胱扩大术可能会提高对 CIC 的满意度。
NBRG 登记处是一项多中心、前瞻性、观察性研究,询问 SCI 参与者有关神经源性膀胱(NGB)相关生活质量(QoL)的问题。在这项研究中,作为主要膀胱管理进行 CIC 的参与者分为 3 组:(1)单独 CIC(CIC);(2)CIC 加肉毒毒素(CIC-BTX);和(3)CIC 加膀胱扩大术(CIC-AUG)。结果包括主要指标:神经源性膀胱症状评分(NBSS)和 SCI-QoL 膀胱管理困难,以及次要指标:NBSS 子域(失禁、存储和排空、后果)和 NBSS 最终问题(对排尿功能的满意度)。使用多变量回归,控制多种因素,以确定三组之间的差异。
879 名参与者作为主要膀胱管理进行 CIC,具有以下特征:平均年龄 43.4(±12.9)岁,损伤后 13.7(±10.7)年,四肢瘫痪 284 例(32%),543 例(62%)为男性。593 例(67%)接受 CIC 管理,161 例(19%)接受 CIC-BTX 治疗,125 例(15%)接受 CIC-AUG 治疗。主要结果:与 CIC 相比,CIC-AUG 与总 NBSS 改善相关(-3.2(-5.2 至-1.2),P=0.001 和 CIC-BTX(-3.9(-6.3 至-1.6),P=0.001),CIC-AUG 还与更好的 SCI-QoL 困难评分相关(与 CIC(-4(-5.48 至-2.53)相比,P<0.001)和 CIC-BTX(-4.4(-6.15 至-2.65)相比,P<0.001)。
与 CIC 和 CIC-BTX 相比,CIC-AUG 与改善的失禁和满意度评分相关。
与接受肉毒毒素治疗或不接受肉毒毒素治疗的 CIC 患者相比,接受膀胱扩大术的患者与更好的尿功能和对其排尿症状的满意度相关。